HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Lu Wang, MD, PhD

Status and phase

Invitation-only

Phase 2

Conditions

Biliary Tract Adenocarcinoma

Treatments

Drug: Gemcitabine

Drug: Donafenib

Drug: Toripalimab

Drug: Oxaliplatin

Procedure: HAIC

Study type

Interventional

Funder types

Other

Identifiers

NCT05350943

2021-GZWK-04

Details and patient eligibility

About

This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer.

Enrollment

70 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

18 to 80 years of age, of any sex;
Histologically/Cytologically confirmed diagnosis of unresectable advanced adenocarcinoma of the gallbladder, intrahepatic bile duct and extrahepatic bile duct.
At least one measurable lesion umder CT/MRI as defined by RECIST1.1 criteria
Patients must have adequate organ and marrow function as defined below:

Blood test:

Hemoglobin (HB) ≥90 g/L Absolute neutrophil count (ANC) ≥1.5×10^9/L； Platelet (PLT) ≥80×10^9/L；

Biochemical test:

total bilirubin≤2×ULN (institutional upper limit of norm) AST(SGOT)/ALT(SGPT)≤2.5 ×ULN creatinine clearance≥ 50 ml/min as calculated by the Cockroft-Gault formula

Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;
Indocyanine Green Retention Rates at 15 min (ICGR15<22%;
Life expectancy of > 3 months;

Exclusion Criteria

Patients with other malignant tumors should be excluded
Female patients who are pregnant or breast-feeding. Female patients who are pregnant during the study should also exit.
Patient has enter any other clinical trails within 4 weeks prior to study entry.
Patient known with a severe and/or uncontrolled medical disease.
Chronic non-healing wound/bone fracture
History of organ transplant
Patients with abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L), those have bleeding tendency (14 days prior to randomization must meet: INR is within the normal range without any use of anticoagulants); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or analogous therapy; use for preventive purposes is permitted provided that the international normalized ratio of prothrombin time (INR) ≤ 1.5, take low-dose warfarin (1 mg PO, QD) or low-dose aspirin (do not exceed 100 mg per day);
Previous history of aterial/venous thrombosis such as cerebrovascular accidents, pulmonary embolism or deep venous thrombosis within one year prior to patients recruitment.
Hitstory of psychiatric drug abuse and hasn't come clean, or with psychiatric illness/social situations that would limit compliance with study requirements
History of immunodeficiency, or other acquired/congenital immunodeficiency diseases
Concomitant diseases that severely endanger the safety of the subject or affect the study completion according to the judgment of the investigator
Willingness to sign a written informed consent document, with good compliance.